Back

Highlights from HELIOS-B - Primary results from phase 3 study of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy

2 September 2024 (07:15 - 07:26)
Organised by: Logo
Congress Presentation Part of: Daily Highlights by the Taiwan Society of Cardiology European Society of Cardiology ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Yen-Wen Wu

Far Eastern Memorial Hospital, New Taipei (Taiwan)

3 More presentations in this session

Presentation thumbnail
Highlights on 2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension and from BedMed/BedMed-Frail
Professor T. Wang (Taipei, TW)
Slides Video
Presentation thumbnail
Highlights from FINEARTS-HF and FINE-HEART: the role of finerenone in heart failure
Professor P. Liu (Tainan, TW)
Slides Video
Presentation thumbnail
Daily Highlights by the Taiwan Society of Cardiology - panel discussion
Video

Access the full session

Session thumbnail
Daily Highlights by the Taiwan Society of Cardiology
Video

The Event

Event poster

ESC Congress 2024

2 September 2024 07:15 CET
You may be interested in
thumbnail
Congress Presentation
HELIOS-B - Primary results from phase 3 study of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy
thumbnail
Congress Presentation
HELIOS-B: 12-month results from the open-label extension period of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy
thumbnail
Congress Presentation
Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy in HELIOS-B who had progressed on tafamidis

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources